UNSPSC 51111856: Lapatinib

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C29H26CLFN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VUA21238F. European Medicines Agency schedules lapatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25379. The term LAPATINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 1, 2004, list 51). Most nations schedule lapatinib under HS 29349990 and SITC 51579.

As of Q4 2014, LAPATINIB remains the US FDA Preferred Term for this commodity. Lapatinib bears US NLM identifiers UMLS ID C1506770 and NCI Concept Code C26653. SMILES: CLC1CC(NC2NCNC3C2CC(C2OC(CNCCS(=O)(=O)C)CC2)CC3)CCC1OCC1CC(F)CCC1.

UNSPSC 51111856 Lapatinib, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing agreements, specifically generic multi-source pharmaceuticals and over-the-counter products distributed to government health facilities and institutions. State and local governments procure under this code primarily through multistate cooperative purchasing vehicles rather than individual agency solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body identified in recent activity, serving participating state and local government facilities across multiple states including Oregon. Vendors supply products through authorized pharmaceutical wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), and successful bidders must maintain contractual relationships with at least two of the three designated wholesalers, possess current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, and offer flexible pricing structures including flat price, net price formats, or WAC-minus pricing models. Evaluations emphasize price competitiveness (75 percent weight) alongside compliance with administrative data format and EDI capability requirements, with awarded vendors paying a 3 percent administrative fee on all contract purchases.

MMCAP issued its most recent RFP (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, seeking multiple contract awards for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, through June 30, 2028. The solicitation does not disclose specific award values or budget ranges but establishes a two-year contract term for new responders with optional extensions at MMCAP's sole discretion. Vendors must maintain comprehensive insurance coverage including $5,000,000 commercial general liability per occurrence, $2,000,000 network security and privacy liability, and $2,000,000 professional liability, and all products must comply with FDA requirements with expiration dates at least one year from manufacture and a minimum six-month shelf life. Submissions were required through the ePro procurement system using designated Excel-to-CSV format by March 26, 2026.